Investigational Drug Information for Ibodutant
✉ Email this page to a colleague
What is the development status for investigational drug Ibodutant?
Ibodutant is an investigational drug.
There have been 5 clinical trials for Ibodutant.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2014.
The most common disease conditions in clinical trials are Syndrome, Irritable Bowel Syndrome, and Diarrhea. The leading clinical trial sponsors are Menarini Group and [disabled in preview].
Summary for Ibodutant
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 27 |
| WIPO Patent Applications | 26 |
| Japanese Patent Applications | 11 |
| Clinical Trial Progress | Phase 3 (2014-02-01) |
| Vendors | 21 |
Recent Clinical Trials for Ibodutant
| Title | Sponsor | Phase |
|---|---|---|
| 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Menarini Group | Phase 3 |
| 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Menarini Group | Phase 3 |
| 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Menarini Group | Phase 3 |
Clinical Trial Summary for Ibodutant
Top disease conditions for Ibodutant
Top clinical trial sponsors for Ibodutant
US Patents for Ibodutant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
